Topical rapamycin (sirolimus) for facial angiofibromas
| العنوان: | Topical rapamycin (sirolimus) for facial angiofibromas |
|---|---|
| المؤلفون: | Bhushan Madke |
| المصدر: | Indian Dermatology Online Journal, Vol 4, Iss 1, Pp 54-57 (2013) Indian Dermatology Online Journal |
| بيانات النشر: | Wolters Kluwer Medknow Publications, 2013. |
| سنة النشر: | 2013 |
| مصطلحات موضوعية: | Facial angiofibromas, business.industry, Tuberous sclerosis, Pharmacology, Mechanism of action, lcsh:RL1-803, medicine.disease, Pulmonary lymphangiomyomatosis, Drug Profile, Sirolimus, medicine, lcsh:Dermatology, Rapamycin, medicine.symptom, Protein kinase A, business, PI3K/AKT/mTOR pathway, medicine.drug, Renal angiomyolipoma |
| الوصف: | Rapamycin (sirolimus) is a fungal fermentation product that inhibits the proper functioning of a serine/threonine protein kinase in mammalian cells eponymously named mammalian target of rapamycin, or mTOR. Rapamycin is a novel class of anticancer and immunosuppressant drugs targeting the proteins at molecular level. Rapamycin (sirolimus) is routinely incorporated in drug-eluting stents used for cardiac angioplasty. In recent years, rapamycin was found to be efficacious in managing the symptom complex of tuberous sclerosis, i.e. renal angiomyolipoma, giant cell astrocytoma and pulmonary lymphangiomyomatosis. Various investigators have also proved that topically applied rapamycin causes regression of facial angiofibromas, giving better cosmetic results. |
| اللغة: | English |
| تدمد: | 2229-5178 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fc28c1a98000ce415c2ac1a3053a0a4Test http://www.idoj.in/article.asp?issn=2229-5178;year=2013;volume=4;issue=1;spage=54;epage=57;aulast=MadkeTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....7fc28c1a98000ce415c2ac1a3053a0a4 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 22295178 |
|---|